Edition:
United Kingdom

Prophase Labs Inc (PRPH.OQ)

PRPH.OQ on NASDAQ Stock Exchange Capital Market

2.39USD
22 Feb 2018
Change (% chg)

$0.02 (+0.84%)
Prev Close
$2.37
Open
$2.39
Day's High
$2.39
Day's Low
$2.35
Volume
3,133
Avg. Vol
1,604
52-wk High
$2.50
52-wk Low
$1.78

Chart for

About

ProPhase Labs, Inc. manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company's products include TK... (more)
No analyst recommendations are available for .

Overall

Beta: 0.16
Market Cap(Mil.): $33.79
Shares Outstanding(Mil.): 16.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 22.59 16.60
EPS (TTM): -- -- --
ROI: -- 12.23 10.66
ROE: -- 15.61 14.30

BRIEF-Prophase Labs Announces New Compensatory Arrangement With CEO And Termination Of Stockholder Rights Plan

* PROPHASE LABS, INC. ANNOUNCES NEW COMPENSATORY ARRANGEMENT WITH CHIEF EXECUTIVE OFFICER AND TERMINATION OF STOCKHOLDER RIGHTS PLAN

21 Feb 2018

BRIEF-ProPhase Labs quarterly loss per share $0.05 from continuing operations

* ProPhase Labs reports financial results for the three months and nine months ended September 30, 2017

13 Nov 2017

BRIEF-Prophase Labs intends to commence tender offer to repurchase up to 1.7 mln shares

* Prophase Labs, Inc. announces intention to commence tender offer to repurchase up to 1,700,000 shares of its common stock

10 Nov 2017

BRIEF-BML Investment Partners reports 5.05 pct passive stake in ProPhase Labs

* BML Investment Partners Lp reports 5.05 percent passive stake in ProPhase Labs Inc ‍​as of September 29 - SEC filing Source: (http://bit.ly/2yjT6PY) Further company coverage:

02 Oct 2017

BRIEF-ProPhase Labs, Inc. announces final results of its tender offer

* ProPhase Labs, Inc. Announces final results of its tender offer

29 Sep 2017

BRIEF-Prophase labs says ‍to purchase up to 4 mln shares of its common stock at a price of $2.30 per share​

* Prophase Labs Inc - ‍to purchase up to 4 million shares of its common stock at a price of $2.30 per share​ Source text for Eikon: Further company coverage:

26 Sep 2017

BRIEF-ProPhase Labs CFO Robert Cuddihy to resign

* Says ‍on August 22, CFO Robert V. Cuddihy Jr., notified company of his intention to resign - SEC filing​

24 Aug 2017

Earnings vs. Estimates

No consensus analysis data available.